scholarly journals A Potential Synbiotic Strategy for the Prevention of Type 2 Diabetes: Lactobacillus paracasei JY062 and Exopolysaccharide Isolated from Lactobacillus plantarum JY039

Nutrients ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 377
Author(s):  
Jiayuan Zhao ◽  
Lihan Wang ◽  
Shasha Cheng ◽  
Yu Zhang ◽  
Mo Yang ◽  
...  

The disturbance of intestinal microorganisms and the exacerbation of type 2 diabetes (T2D) are mutually influenced. In this study, the effect of exopolysaccharides (EPS) from Lactobacillus plantarum JY039 on the adhesion of Lactobacillus paracasei JY062 was investigated, as well as their preventive efficacy against T2D. The results showed that the EPS isolated from L. plantarum JY039 effectively improved the adhesion rate of L. paracasei JY062 to Caco-2 cells (1.8 times) and promoted the proliferation of L. paracasei JY062. In the mice experiment, EPS, L. paracasei JY062 and their complex altered the structure of the intestinal microbiota, which elevated the proportion of Bifidobacterium, Faecalibaculum, while inversely decreasing the proportion of Firmicutes, Muribaculaceae, Lachnospiraceae and other bacteria involved in energy metabolism (p < 0.01; p < 0.05); enhanced the intestinal barrier function; promoted secretion of the gut hormone peptide YY (PYY) and glucagon-like peptide-1 (GLP-1); and reduced inflammation by balancing pro-inflammatory factors IL-6, TNF-α and anti-inflammatory factor IL-10 (p < 0.01; p < 0.05). These results illustrate that EPS and L. paracasei JY062 have the synbiotic potential to prevent and alleviate T2D.

2017 ◽  
Vol 312 (4) ◽  
pp. C438-C445 ◽  
Author(s):  
Jing Wang ◽  
Siddhartha S. Ghosh ◽  
Shobha Ghosh

Association between circulating lipopolysaccharide (LPS) and metabolic diseases (such as type 2 diabetes and atherosclerosis) has shifted the focus from high-fat high-cholesterol containing Western-type diet (WD)-induced changes in gut microbiota per se to release of gut bacteria-derived products (e.g., LPS) into circulation due to intestinal barrier dysfunction as the possible mechanism for the chronic inflammatory state underlying the development of these diseases. We demonstrated earlier that oral supplementation with curcumin attenuates WD-induced development of type 2 diabetes and atherosclerosis. Poor bioavailability of curcumin has precluded the establishment of a causal relationship between oral supplementation and it is in vivo effects. We hypothesized that curcumin attenuates WD-induced chronic inflammation and associated metabolic diseases by modulating the function of intestinal epithelial cells (IECs) and the intestinal barrier function. The objective of the present study was to delineate the underlying mechanisms. The human IEC lines Caco-2 and HT-29 were used for these studies and modulation of direct as well as indirect effects of LPS on intracellular signaling as well as tight junctions were examined. Pretreatment with curcumin significantly attenuated LPS-induced secretion of master cytokine IL-1β from IECs and macrophages. Furthermore, curcumin also reduced IL-1β-induced activation of p38 MAPK in IECs and subsequent increase in expression of myosin light chain kinase involved in the phosphorylation of tight junction proteins and ensuing disruption of their normal arrangement. The major site of action of curcumin is, therefore, likely the IECs and the intestinal barrier, and by reducing intestinal barrier dysfunction, curcumin modulates chronic inflammatory diseases despite poor bioavailability.


2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Li Zheng ◽  
Wei Zhang ◽  
Aimei Li ◽  
Yan Liu ◽  
Bin Yi ◽  
...  

Objective. Inflammation plays a major role in albuminuria in type 2 diabetes mellitus (T2DM). Our previous studies have shown that the expression of vitamin D receptor (VDR) is downregulated in T2DM which is closely associated with the severity of albuminuria. In this study, we investigated the expression of anti-inflammatory cytokine protein tyrosine phosphatase nonreceptor type 2 (PTPN2) in T2DM and explored its relationship to albuminuria and VDR. Methods. 101 T2DM patients were divided into three groups based on urinary albumin-to-creatinine ratio (uACR): normal albuminuria (uACR < 30 mg/g, n=29), microalbuminuria (30 mg/g ≤ uACR < 300 mg/g, n=34), and macroalbuminuria (uACR ≥ 300 mg/g, n=38). Thirty healthy individuals were included as controls. Serum was analyzed for PTPN2 and IL-6 expression, and peripheral blood mononuclear cells (PBMCs) were analyzed for PTPN2 and VDR expression. THP-1 cells were incubated with high glucose and further treated with or without paricalcitol, a vitamin D analog. The levels of PTPN2, VDR, IL-6, TNFα, and MCP-1 were analyzed. In addition, anti-inflammatory activities of PTPN2 were further explored in THP-1 cells stimulated with high glucose after PTPN2 silencing or overexpression. Results. PTPN2 expression was downregulated in T2DM with the lowest level observed in macroalbuminuria patients. PTPN2 level positively correlated with VDR but negatively correlated with uACR and IL-6. When stimulated with high glucose, there was an increase in inflammatory factors and a decrease in PTPN2 expression. Treatment with paricalcitol reversed these effects. However, paricalcitol failed to exert anti-inflammatory effects in the setting of PTPN2 knockdown. Thus, low levels of PTPN2 aggravated glucose-stimulated inflammation, while high levels of PTPN2 reduced it. Conclusion. PTPN2, an anti-inflammatory factor regulated by VDR, was reduced in T2DM CKD stages 1-2. Taken together, our results suggest that therapeutic strategies that enhance PTPN2 may be beneficial for controlling inflammation in T2DM.


2021 ◽  
Author(s):  
Ishwari Gyawali ◽  
Guilian Zhou ◽  
Guli Xu ◽  
Yuxian Zeng ◽  
Jincheng Li ◽  
...  

Abstract Background: The beneficial impact of probiotics on host health is impaired due to the significant loss of survivability during gastric transit, small intestinal enzymes, and bile acids. Encapsulation helps to preserve the probiotics species from severe environmental factors. This study investigated the effects of oral delivery of probiotics via microcapsule on different parameters of gut health. Methods: Lactobacillus paracasei, highly sensitive probiotic species to gastric acid, was encapsulated with novel encapsulating material, polyacrylate resin, to get a microcapsule. C57BL/6 male mice were equally divided into three groups; supplementing basal feed, a mixture of encapsulating material and Lactobacillus paracasei, and encapsulated Lactobacillus paracasei (microcapsule) for four weeks. Fecal moisture percentage was measured regularly, which was elevated in the encapsulated group, but not in the mixed group. Based on this data, mice from control and encapsulated groups were sacrificed to study the different parameters of gut health. Results: Compared to control, encapsulated probiotics increased villi height, the ratio of villi height to crypt depth, and decreased crypt depth. Simultaneously, the tight junction proteins were upregulated on encapsulated group showing enhancement of intestinal barrier functions. The level of SigA and mucin increased along with gene expression of MUC-2 but, albumin level was decreased. In addition, we found a rise in the relative gene expression of anti-inflammatory factor (IL-10) and decreased pro-inflammatory factors (IL-1β, IL-6, IL-8, and TNF-α). Meanwhile, microbiota metabolites, fecal LPS and TMAO were downregulated while SCFA and lactate were upraised compared to control. Furthermore, GSH-Px and TAOC level were increased and MDA was decreased. Microbiota analysis revealed the proportion of firmicutes was higher at the phylum level on an encapsulated group, while Lactobacillus was elevated at the genus level. We also found a remarkable increase in the population of Lactobacillus murinus at the species level. In summary, the oral delivery of probiotics via microcapsule effectively improves the animals' gut health by improving morphology, barrier function, anti-inflammatory action, antioxidant ability and modulating gut microbiota.


2021 ◽  
Vol 30 (3) ◽  
pp. 309-317
Author(s):  
Moon-Ju Kim ◽  
Kyeong-Lae Kim ◽  
Min-Ji An

PURPOSE: The purpose of this study was to investigate the effect of resistance ladder exercise on myocardial inflammatory cytokines and extracellular signal regulated kinase (ERK)1/2 expression in type 2 diabetic rats.METHODS: A total of 21 8-week-old male Long Evans Tokushima Otsuka (LETO) and Otsuka Long Evans Tokushima Fatty (OLETF) rats were divided into three groups: LETO group (CON, n=7), OLETF group (DM, n=7), and resistance exercise group (DM+EXE, n=7). Resistance exercise referred to a climbing exercise on a slope. The rats performed this exercise 3 full d per week, for 8 week. The expression of myocardial inflammatory cytokines and ERK1/2 was analyzed via western blotting after 8 week of exercise intervention.RESULTS: After 8 weeks of resistance exercise for the management of type 2 diabetes, the production of anti-inflammatory factor Interleukin (IL)-10 in the myocardium increased. This inhibited the production of pro-inflammatory factors IL-6 and tumor necrosis factor-alpha. However, resistance exercise did not affect the expression of ERK1 and ERK2, which are apoptosis regulatory proteins.CONCLUSIONS: In type 2 diabetes, resistance exercise is thought to be effective in reducing inflammatory factors by mediating cytokines. Although the effects of resistance ladder exercise were confirmed, further studies on a variety of exercise types and intensities should be conducted to prevent and improve the conditions of those with diabetes.


Author(s):  
A. L. Cunningham ◽  
J. W. Stephens ◽  
D. A. Harris

AbstractObesity and type 2 diabetes mellitus (T2DM) are common, chronic metabolic disorders with associated significant long-term health problems at global epidemic levels. It is recognised that gut microbiota play a central role in maintaining host homeostasis and through technological advances in both animal and human models it is becoming clear that gut microbiota are heavily involved in key pathophysiological roles in the aetiology and progression of both conditions. This review will focus on current knowledge regarding microbiota interactions with short chain fatty acids, the host inflammatory response, signaling pathways, integrity of the intestinal barrier, the interaction of the gut-brain axis and the subsequent impact on the metabolic health of the host.


1998 ◽  
Vol 95 (6) ◽  
pp. 719-724 ◽  
Author(s):  
C. Mark B. EDWARDS ◽  
Jeannie F. TODD ◽  
Mohammad A. GHATEI ◽  
Stephen R. BLOOM

1. Glucagon-like peptide-1 (7-36) amide (GLP-1) is a gut hormone released postprandially that stimulates insulin secretion, suppresses glucagon secretion and delays gastric emptying. The insulinotropic action of GLP-1 is more potent under hyperglycaemic conditions. Several published studies have indicated the therapeutic potential of subcutaneous GLP-1 in non-insulin-dependent (Type 2) diabetes mellitus. 2. We investigated whether subcutaneous GLP-1, at a dose shown to improve glycaemic control in early Type 2 diabetes, is insulinotropic at normal fasting glucose concentrations. A double-blind, randomized, crossover study of 10 healthy subjects injected with GLP-1 or saline subcutaneously after a 16 h fast was performed. The effect on cardiovascular parameters was also examined. 3. GLP-1 caused a near 5-fold rise in plasma insulin concentration. After treatment with GLP-1, circulating plasma glucose concentrations fell below the normal range in all subjects. One subject had symptoms of hypoglycaemia after GLP-1. A rise in pulse rate was found which correlated with the fall in plasma glucose concentration. An increase in blood pressure occurred with GLP-1 injection which was seen at the same time as the rise in plasma GLP-1 concentrations. 4. This study indicates that subcutaneous GLP-1 can override the normal homoeostatic mechanism maintaining fasting plasma glucose in man, and is also associated with an increase in blood pressure.


Sign in / Sign up

Export Citation Format

Share Document